Werewolf Therapeutics Valuation
| HOWL Stock | USD 0.68 0.02 3.03% |
Werewolf Therapeutics is fairly valued. Werewolf Therapeutics maintains a prevalent Real Value of $0.66 per share. The last-minute price of the company is $0.68. Our model calculates the value of Werewolf Therapeutics from examining the company fundamentals such as Current Valuation of 6.76 M, shares owned by insiders of 5.61 %, and Return On Asset of -0.41 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Werewolf Therapeutics' valuation include:
Price Book 1.0844 | Enterprise Value | Enterprise Value Ebitda 0.5683 | Price Sales 52.2151 | Enterprise Value Revenue 0.6742 |
Fairly Valued
Today
Please note that Werewolf Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Werewolf Therapeutics is based on 3 months time horizon. Increasing Werewolf Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Werewolf stock is determined by what a typical buyer is willing to pay for full or partial control of Werewolf Therapeutics. Since Werewolf Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Werewolf Stock. However, Werewolf Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.68 | Real 0.66 | Target 5.2 | Hype 0.68 | Naive 0.7 |
The intrinsic value of Werewolf Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Werewolf Therapeutics' stock price.
Estimating the potential upside or downside of Werewolf Therapeutics helps investors to forecast how Werewolf stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Werewolf Therapeutics more accurately as focusing exclusively on Werewolf Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Werewolf Therapeutics' intrinsic value based on its ongoing forecasts of Werewolf Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Werewolf Therapeutics' closest peers.
Werewolf Therapeutics Cash |
|
Werewolf Therapeutics Total Value Analysis
Werewolf Therapeutics is currently anticipated to have valuation of 6.76 M with market capitalization of 32.11 M, debt of 37.09 M, and cash on hands of 145.71 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Werewolf Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.76 M | 32.11 M | 37.09 M | 145.71 M |
Werewolf Therapeutics Investor Information
About 42.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.08. Some equities with similar Price to Book (P/B) outperform the market in the long run. Werewolf Therapeutics recorded a loss per share of 1.62. The entity had not issued any dividends in recent years. Based on the key indicators related to Werewolf Therapeutics' liquidity, profitability, solvency, and operating efficiency, Werewolf Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Werewolf Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Werewolf Therapeutics has an asset utilization ratio of 1.49 percent. This suggests that the Company is making $0.0149 for each dollar of assets. An increasing asset utilization means that Werewolf Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Werewolf Therapeutics Profitability Analysis
Based on Werewolf Therapeutics' profitability indicators, Werewolf Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Werewolf Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2020-03-31 | Previous Quarter -18 M | Current Value -16.4 M | Quarterly Volatility 5.6 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0411 | 0.0433 |
|
|
For Werewolf Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Werewolf Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Werewolf Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Werewolf Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Werewolf Therapeutics over time as well as its relative position and ranking within its peers.
Werewolf Therapeutics Earnings per Share Projection vs Actual
By analyzing Werewolf Therapeutics' earnings estimates, investors can diagnose different trends across Werewolf Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Werewolf Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Werewolf Therapeutics Ownership Allocation
Werewolf Therapeutics retains a total of 48.54 Million outstanding shares. 30% of Werewolf Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Werewolf Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.89 M. Net Loss for the year was (70.52 M) with loss before overhead, payroll, taxes, and interest of (50.48 M).About Werewolf Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Werewolf Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Werewolf Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Werewolf Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Werewolf Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Werewolf Therapeutics. We calculate exposure to Werewolf Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Werewolf Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 81.7 K | 77.6 K | |
| Pretax Profit Margin | (43.02) | (40.87) | |
| Operating Profit Margin | (44.90) | (42.65) | |
| Net Loss | (43.02) | (40.87) | |
| Gross Profit Margin | 0.04 | 0.04 |
Werewolf Therapeutics Current Valuation Indicators
Werewolf Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Werewolf Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Werewolf Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Werewolf Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Werewolf Therapeutics' worth.When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.